Pizotifen: Difference between revisions
Content deleted Content added
More pharm. |
|||
| (23 intermediate revisions by 18 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Drug used to reduce frequency of headaches}} |
|||
{{Drugbox |
|||
{{cs1 config|name-list-style=vanc}} |
|||
| Verifiedfields = changed |
|||
{{Infobox drug |
|||
| Verifiedfields = verified |
|||
| verifiedrevid = 464208411 |
| verifiedrevid = 464208411 |
||
| IUPAC_name = 4-(1-methyl-4-piperidylidine)-9,10-dihydro -4''H''-benzo-[4,5]cyclohepta[1,2]-thiophene |
| IUPAC_name = 4-(1-methyl-4-piperidylidine)-9,10-dihydro -4''H''-benzo-[4,5]cyclohepta[1,2]-thiophene |
||
| image = Pizotifen structure.svg |
| image = Pizotifen structure.svg |
||
| width = |
| width = 180px |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Sandomigran |
| tradename = Sandomigran, Mosegor, Litec, others |
||
| Drugs.com = {{drugs.com|international|pizotifen}} |
| Drugs.com = {{drugs.com|international|pizotifen}} |
||
| pregnancy_AU = B1 |
| pregnancy_AU = B1 |
||
| Line 17: | Line 19: | ||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = Oral |
| routes_of_administration = [[Oral administration|Oral]] |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| Line 27: | Line 29: | ||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|correct|CAS}} |
||
| CAS_number = 15574-96-6 |
| CAS_number = 15574-96-6 |
||
| ATC_prefix = N02 |
| ATC_prefix = N02 |
||
| Line 34: | Line 36: | ||
| IUPHAR_ligand = 93 |
| IUPHAR_ligand = 93 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = DB06153 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 25497 |
| ChemSpiderID = 25497 |
||
| Line 43: | Line 45: | ||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 294951 |
| ChEMBL = 294951 |
||
| synonyms = Pizotyline; BC-105 |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=19 | H=21 | N=1 | S=1 |
| C=19 | H=21 | N=1 | S=1 |
||
| SMILES = s1c3c(cc1)C(\c2c(cccc2)CC3)=C4/CCN(C)CC4 |
|||
| molecular_weight = 295.443 g/mol |
|||
| smiles = s1c3c(cc1)C(\c2c(cccc2)CC3)=C4/CCN(C)CC4 |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3 |
| StdInChI = 1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3 |
||
| Line 54: | Line 56: | ||
}} |
}} |
||
'''Pizotifen''' |
'''Pizotifen''', also known as '''pizotyline''' and sold under the brand names '''Sandomigran''' and '''Mosegor''' among others, is an [[antimigraine agent]] of the [[tricyclic compound|tricyclic]] group which is used primarily as a [[prophylaxis|preventative]] to reduce the frequency of recurrent [[migraine]] headaches.<ref name="pmid17680738">{{cite journal | vauthors = Stark RJ, Valenti L, Miller GC | title = Management of migraine in Australian general practice | journal = The Medical Journal of Australia | volume = 187 | issue = 3 | pages = 142–146 | date = August 2007 | pmid = 17680738 | doi = 10.5694/j.1326-5377.2007.tb01170.x | s2cid = 10357983 }}</ref> |
||
== |
==Medical uses== |
||
===Migraine headaches=== |
|||
The main medical use for pizotifen is for the prevention of [[migraine]] and [[cluster headache]]. Pizotifen is one of a range of medications used for this purpose, other options include [[propranolol]], [[topiramate]], [[valproic acid]] and [[amitriptyline]]. While pizotifen is reasonably effective,<ref>Barnes N, Millman G. Do pizotifen or propranolol reduce the frequency of migraine headache? Archives of Disease in Childhood. 2004 Jul;89(7):684-5.</ref> its use is limited by side effects, principally drowsiness and weight gain, and it is usually not the first choice medicine for preventing migraines, instead being used as an alternative when other drugs have failed to be effective.<ref>Pierangeli G, Cevoli S, Sancisi E, Grimaldi D, Zanigni S, Montagna P, Cortelli P. Which therapy for which patient? Neurological Sciences. 2006 May;27 Suppl 2:S153-8.</ref> It is not effective in relieving migraine attacks once in progress. Pizotifen has also been reported as highly effective in a severe case of erythromelalgia, a rare neurovascular disease that is sometimes refractory to the other drugs named above.<ref>Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):841-7</ref> |
|||
The main medical use for pizotifen is for the prevention of [[migraine]] and [[cluster headache]]. Pizotifen is one of a range of medications used for this purpose, other options include [[propranolol]], [[topiramate]], [[valproic acid]], [[cyproheptadine]] and [[amitriptyline]]. While pizotifen is effective in adults,<ref>{{cite journal | vauthors = Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J | display-authors = 6 | title = A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache | journal = PLOS ONE | volume = 10 | issue = 7 | pages = e0130733 | date = 2015-07-14 | pmid = 26172390 | pmc = 4501738 | doi = 10.1371/journal.pone.0130733 | doi-access = free | bibcode = 2015PLoSO..1030733J }}</ref> evidence of efficacy in children is limited,<ref name="pmid15210509">{{cite journal | vauthors = Barnes N, Millman G | title = Do pizotifen or propranolol reduce the frequency of migraine headache? | journal = Archives of Disease in Childhood | volume = 89 | issue = 7 | pages = 684–685 | date = July 2004 | pmid = 15210509 | pmc = 1719986 | doi = 10.1136/adc.2004.054668 }}</ref> and its use is limited by side effects, principally drowsiness and weight gain, and it is usually not the first choice medicine for preventing migraines, instead being used as an alternative when other drugs have failed to be effective.<ref>{{cite journal | vauthors = Pierangeli G, Cevoli S, Sancisi E, Grimaldi D, Zanigni S, Montagna P, Cortelli P | title = Which therapy for which patient? | journal = Neurological Sciences | volume = 27 | issue = Suppl 2 | pages = S153–S158 | date = May 2006 | pmid = 16688621 | doi = 10.1007/s10072-006-0592-0 | s2cid = 24217802 }}</ref> It is not effective in relieving migraine attacks once in progress. |
|||
===Other uses=== |
|||
Other applications for which pizotifen may be used include as an [[antidepressant]], or for the treatment of [[anxiety]] or [[social anxiety disorder|social phobia]].<ref>Standal JE. Pizotifen as an antidepressant. [[Acta Psychiatrica Scandinavica]]. 1977 Oct;56(4):276-9.</ref><ref>Banki CM. Clinical observations with pizotifene (Sandomigran) in the treatment of nonmigrainous depressed women. Archiv für Psychiatrie und Nervenkrankheiten. 1978 Mar 7;225(1):67-72.</ref> Animal studies also suggest that pizotyline could be used in the treatment of [[serotonin syndrome]] or [[MDMA]] [[overdose]]<ref>Young R, Khorana N, Bondareva T, Glennon RA. Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA). Pharmacology Biochemistry and Behavior. 2005 Oct;82(2):404-10.</ref> in a similar manner to the closely related antihistamine/antiserotonin medication [[cyproheptadine]]. |
|||
Pizotifen has also been reported as highly effective in a severe case of [[erythromelalgia]], a rare neurovascular disease that is sometimes refractory to the other drugs named above.<ref name="pmid11050591">{{cite journal | vauthors = Cohen JS | title = Erythromelalgia: new theories and new therapies | journal = Journal of the American Academy of Dermatology | volume = 43 | issue = 5 Pt 1 | pages = 841–847 | date = November 2000 | pmid = 11050591 | doi = 10.1067/mjd.2000.109301 | s2cid = 40807034 }}</ref> |
|||
Other applications for which pizotifen may be used include as an [[antidepressant]], or for the treatment of [[anxiety]] or [[social anxiety disorder|social phobia]].<ref name="pmid335788">{{cite journal | vauthors = Standal JE | title = Pizotifen as an antidepressant | journal = Acta Psychiatrica Scandinavica | volume = 56 | issue = 4 | pages = 276–279 | date = October 1977 | pmid = 335788 | doi = 10.1111/j.1600-0447.1977.tb00228.x | s2cid = 6445059 }}</ref><ref name="pmid348154">{{cite journal | vauthors = Banki CM | title = Clinical observations with pizotifene (Sandomigran) in the treatment of nonmigrainous depressed women | journal = Archiv für Psychiatrie und Nervenkrankheiten | volume = 225 | issue = 1 | pages = 67–72 | date = March 1978 | pmid = 348154 | doi = 10.1007/bf00367352 | s2cid = 13510725 }}</ref> Animal studies also suggest that pizotyline could be used in the treatment of [[serotonin syndrome]] or [[MDMA]] [[overdose]]<ref name="pmid16253319">{{cite journal | vauthors = Young R, Khorana N, Bondareva T, Glennon RA | title = Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA) | journal = Pharmacology, Biochemistry, and Behavior | volume = 82 | issue = 2 | pages = 404–410 | date = October 2005 | pmid = 16253319 | doi = 10.1016/j.pbb.2005.09.010 | s2cid = 20885754 }}</ref> in a similar manner to the closely related antihistamine/antiserotonin medication [[cyproheptadine]]. |
|||
==Adverse effects== |
|||
[[Adverse drug reaction|Side effects]] include [[sedation]], [[dry mouth]], drowsiness, increased appetite and weight gain.<ref>Crowder D, Maclay WP. Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study. Current Medical Research and Opinion. 1984;9(4):280-5.</ref> Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur. |
|||
Pizotifen might be useful as a [[trip killer|hallucinogen antidote or "trip killer"]] in blocking the effects of [[serotonergic psychedelic]]s like [[psilocybin]].<ref name="HalmanKongSarris2024">{{cite journal | vauthors = Halman A, Kong G, Sarris J, Perkins D | title = Drug-drug interactions involving classic psychedelics: A systematic review | journal = J Psychopharmacol | volume = 38 | issue = 1 | pages = 3–18 | date = January 2024 | pmid = 37982394 | pmc = 10851641 | doi = 10.1177/02698811231211219 | url = }}</ref> It might also be useful in the treatment of [[MDMA]] [[overdose]].<ref name="YoungKhoranaBondareva2005" /> |
|||
==Contraindications== |
==Contraindications== |
||
Caution is required in patients having closed angle [[glaucoma]] and in patients with a predisposition to [[urinary retention]] as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have [[chronic kidney disease]]. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of [[epilepsy]]. |
Caution is required in patients having closed angle [[glaucoma]] and in patients with a predisposition to [[urinary retention]] as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have [[chronic kidney disease]]. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of [[epilepsy]]. |
||
Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen.<ref>{{cite web|url= |
Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen.<ref>{{cite web|url=https://www.medsafe.govt.nz/profs/datasheet/s/Sandomigrantab.pdf|title=SANDOMIGRAN® pizotifen 500 micrograms coated tablets | work = AFT Pharmaceuticals Ltd | date = 21 June 2019 | publisher = Medsafe: New Zealand Medicines and Medical Devices Safety }}</ref> |
||
Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components, also Pizotifen is contraindicated in [[gastric outlet obstruction]], [[pregnancy]], angle-closure glaucoma and difficulty urinating.<ref>{{cite web|url=http://lekarstwo.ru/en/preparati/pizotifen.html|title=Likarstwo.ru}}</ref> |
|||
Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components, also Pizotifen is contraindicated in [[gastric outlet obstruction]], [[pregnancy]], angle-closure glaucoma and difficulty urinating.<ref>{{cite web|url=http://lekarstwo.ru/en/preparati/pizotifen.html | title = Pizotifen | work = Universal reference book of medicines | via = Likarstwo.ru}}</ref> |
|||
==Adverse effects== |
|||
[[Adverse drug reaction|Side effects]] include [[sedation]], [[dry mouth]], drowsiness, increased appetite and weight gain.<ref>Crowder D, Maclay WP. Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study. Current Medical Research and Opinion. 1984;9(4):280-5.</ref> Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur. |
|||
==Pharmacology== |
==Pharmacology== |
||
===Pharmacodynamics=== |
|||
Pizotifen is a [[serotonin antagonist]] acting mainly at the [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[5-HT2C receptor|5HT<sub>2C</sub>]] [[serotonin receptor|receptors]]. It also has some activity as an [[antihistamine]] as well as some anticholinergic activity.<ref>Dixon AK, Hill RC, Roemer D, Scholtysik G. Pharmacological properties of 4-(1-methyl-4-piperidylidine)-9,10-dihydro-4H-benzo-[4,5]cyclohepta[1,2]-thiophene hydrogen maleate (pizotifen). Arzneimittelforschung. 1977;27(10):1968-79.</ref> |
|||
{| class="wikitable floatright" style="font-size:small;" |
|||
|+ {{Nowrap|Pizotifen activities}} |
|||
|- |
|||
! [[Biological target|Target]] !! [[Affinity (pharmacology)|Affinity]] (K<sub>i</sub>, nM) !! Species |
|||
|- |
|||
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 200–270 || Human |
|||
|- |
|||
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || 1415 || Human |
|||
|- |
|||
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || 770 || Human |
|||
|- |
|||
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || 820 || Human |
|||
|- |
|||
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 2.0 || Human |
|||
|- |
|||
| [[5-HT2B receptor|5-HT<sub>2B</sub>]] || 2.0–2.3 || Human |
|||
|- |
|||
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 8.4 || Human |
|||
|- |
|||
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || 95 || Human |
|||
|- |
|||
| [[5-HT4 receptor|5-HT<sub>4</sub>]] || {{Abbr|ND|No data}} || Human |
|||
|- |
|||
| [[5-HT5A receptor|5-HT<sub>5A</sub>]] || 110 || Human |
|||
|- |
|||
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 74 || Human |
|||
|- |
|||
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 17–25 || Human |
|||
|- |
|||
| [[D1 receptor|D<sub>1</sub>]] || 3.5 || Human |
|||
|- |
|||
| [[D2 receptor|D<sub>2</sub>]] || 2.4–87 || Human |
|||
|- |
|||
| [[D3 receptor|D<sub>3</sub>]] || {{Abbr|ND|No data}} || {{Abbr|ND|No data}} |
|||
|- |
|||
| [[D4 receptor|D<sub>4</sub>]] || 64 || Human |
|||
|- |
|||
| [[D5 receptor|D<sub>5</sub>]] || 50 || Human |
|||
|- |
|||
| [[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 65 || Human |
|||
|- |
|||
| [[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || >10000 || Human |
|||
|- |
|||
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 660 || Human |
|||
|- |
|||
| [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] || 225 || Human |
|||
|- |
|||
| [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] || 390 || Human |
|||
|- |
|||
| [[Beta-1 adrenergic receptor|β<sub>1</sub>]] || >10000 || Human |
|||
|- |
|||
| [[Beta-2 adrenergic receptor|β<sub>2</sub>]] || >10000 || Human |
|||
|- |
|||
| [[H1 receptor|H<sub>1</sub>]] || 1.9 || Human |
|||
|- |
|||
| [[H2 receptor|H<sub>2</sub>]] || 1.4 || Human |
|||
|- |
|||
| [[Muscarinic acetylcholine M1 receptor|M<sub>1</sub>]] || 67 || Human |
|||
|- |
|||
| [[Muscarinic acetylcholine M2 receptor|M<sub>2</sub>]] || 34 || Human |
|||
|- |
|||
| [[Muscarinic acetylcholine M3 receptor|M<sub>3</sub>]] || 29 || Human |
|||
|- |
|||
| [[Muscarinic acetylcholine M4 receptor|M<sub>4</sub>]] || 130 || Human |
|||
|- |
|||
| [[Muscarinic acetylcholine M5 receptor|M<sub>5</sub>]] || 6.8 || Human |
|||
|- |
|||
| [[Imidazoline I1 receptor|I<sub>1</sub> receptor]] || 121 || Human |
|||
|- |
|||
| [[Sigma-1 receptor|σ<sub>1</sub> receptor]] || >10000 || Guinea pig |
|||
|- |
|||
| [[Sigma-2 receptor|σ<sub>2</sub> receptor]] || 6450 || Rat |
|||
|- |
|||
| {{Abbrlink|SERT|Serotonin transporter}} || >10000 || Human |
|||
|- |
|||
| {{Abbrlink|NET|Norepinephrine transporter}} || 710 || Human |
|||
|- |
|||
| {{Abbrlink|DAT|Dopamine transporter}} || >10000 || Human |
|||
|- |
|||
| colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Note:''' The smaller the value, the more avidly the compound binds to or activates the site. '''Refs:''' <ref name="PDSP-Ki-Database-Pizotyline">{{cite web | title=PDSP Database | website=UNC | url=https://pdsp.unc.edu/databases/pdsp.php?testFreeRadio=testFreeRadio&testLigand=Pizotyline&kiAllRadio=all&doQuery=Submit+Query | language=zu | access-date=24 November 2024}}</ref><ref name="PDSP-Ki-Database-Pizotifen">{{cite web | title=PDSP Database | website=UNC | url=https://pdsp.unc.edu/databases/pdsp.php?testFreeRadio=testFreeRadio&testLigand=Pizotifen&kiAllRadio=all&doQuery=Submit+Query | language=zu | access-date=24 November 2024}}</ref><ref name="BindingDB">{{cite web | last=Liu | first=Tiqing | title=BindingDB BDBM82088 CAS_15574-96-6::NSC_27400::PIZOTIFEN | website=BindingDB | url=https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=82088 | access-date=24 November 2024}}</ref><ref name="YoungKhoranaBondareva2005">{{cite journal | vauthors = Young R, Khorana N, Bondareva T, Glennon RA | title = Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA) | journal = Pharmacol Biochem Behav | volume = 82 | issue = 2 | pages = 404–410 | date = October 2005 | pmid = 16253319 | doi = 10.1016/j.pbb.2005.09.010 | url = }}</ref><ref name="MoritomoYamadaWatanabe2013">{{cite journal | vauthors = Moritomo A, Yamada H, Watanabe T, Itahana H, Akuzawa S, Okada M, Ohta M | title = Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists | journal = Bioorg Med Chem | volume = 21 | issue = 24 | pages = 7841–7852 | date = December 2013 | pmid = 24189186 | doi = 10.1016/j.bmc.2013.10.010 | url = }}</ref> |
|||
|} |
|||
Pizotifen is a [[serotonin antagonist]] acting mainly at the [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s. It also has some activity as an [[antihistamine]] as well as some [[anticholinergic]] activity.<ref name="pmid411500">{{cite journal | vauthors = Dixon AK, Hill RC, Roemer D, Scholtysik G | title = Pharmacological properties of 4(1-methyl-4-piperidylidine)-9,10-dihydro-4H-benzo-[4,5]cyclohepta[1,2]-thiophene hydrogen maleate (pizotifen) | journal = Arzneimittel-Forschung | volume = 27 | issue = 10 | pages = 1968–1979 | date = 1977 | pmid = 411500 }}</ref> The drug binds [[binding selectivity|non-selective]]y to many [[biological target|target]]s, including [[serotonin receptor|serotonin]], [[dopamine receptor|dopamine]], [[adrenergic receptor|adrenergic]], [[histamine receptor|histamine]], and [[muscarinic acetylcholine receptor]]s.<ref name="YoungKhoranaBondareva2005" /> |
|||
Pizotifen is able to [[dose dependence|dose-dependently]] and fully antagonize the [[discriminative stimulus]] effects of the [[serotonin–norepinephrine–dopamine releasing agent]] and [[serotonin]] [[5-HT2 receptor|5-HT<sub>2</sub> receptor]] [[agonist]] [[MDMA]] in rodent [[drug discrimination]] tests.<ref name="YoungKhoranaBondareva2005" /> Conversely, the related drug [[cyproheptadine]] was only partially effective and [[clozapine]] was ineffective.<ref name="YoungKhoranaBondareva2005" /> All three of these agents, pizotifen, cyproheptadine, and clozapine act as non-selective [[monoamine receptor]] antagonists.<ref name="YoungKhoranaBondareva2005" /> Pizotifen also fully blocks the effects of [[serotonergic psychedelic]]s, including [[LSD]], [[mescaline]], [[5-MeO-DMT]], and [[DOM (drug)|DOM]], in drug discrimination tests.<ref name="YoungKhoranaBondareva2005" /> |
|||
==Chemistry== |
|||
Pizotifen is a [[tricyclic compound]] and is specifically a [[benzocycloheptene]].<ref name="Elks2014" /><ref name="IndexNominum2004" /> |
|||
Close [[structural analog|analogue]]s of pizotifen include [[ketotifen]] and [[cyproheptadine]], among others. |
|||
==History== |
|||
Pizotifen was first described in the literature by 1964.<ref name="Elks2014" /> |
|||
==Society and culture== |
|||
===Names=== |
|||
''Pizotifen'' is the [[generic term|generic name]] of the drug and its {{Abbrlink|INN|International Nonproprietary Name}} and {{Abbrlink|BAN|British Approved Name}}, while ''pizotyline'' is its {{Abbrlink|USAN|United States Adopted Name}}.<ref name="Elks2014">{{cite book | last=Elks | first=J. | title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies | publisher=Springer US | year=2014 | isbn=978-1-4757-2085-3 | url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1002 | access-date=24 November 2024 | page=1002}}</ref><ref name="IndexNominum2004">{{cite book | author=Schweizerischer Apotheker-Verein | title=Index Nominum: International Drug Directory | publisher=Medpharm Scientific Publishers | series=Index Nominum: International Drug Directory | year=2004 | isbn=978-3-88763-101-7 | url=https://books.google.com/books?id=EgeuA47Ocm4C&pg=PA992 | access-date=24 November 2024 | page=992}}</ref><ref name="MortonHall2012">{{cite book | last=Morton | first=I.K. | last2=Hall | first2=J.M. | title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms | publisher=Springer Netherlands | year=2012 | isbn=978-94-011-4439-1 | url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA225 | access-date=24 November 2024 | page=225}}</ref> Brand names of pizotifen include Sandomigran, Mosegor, and Litec, among others.<ref name="Elks2014" /><ref name="IndexNominum2004" /><ref name="MortonHall2012" /><ref name="Drugs.com-International" /> |
|||
== |
===Availability=== |
||
Pizotifen is available widely throughout the world, including in [[Europe]].<ref name="IndexNominum2004" /><ref name="Drugs.com-International">{{cite web | title=Pizotifen (International database) | website=Drugs.com | date=3 November 2024 | url=https://www.drugs.com/international/pizotifen.html | access-date=24 November 2024}}</ref> |
|||
* [[Benzocycloheptene]] |
|||
* [[Cyproheptadine]] |
|||
* [[Ketotifen]] |
|||
==References== |
== References == |
||
{{Reflist |
{{Reflist}} |
||
==External links== |
== External links == |
||
* [http://www.medsafe.govt.nz/profs/datasheet/s/Sandomigrantab.pdf Sandomigran drug data sheet] |
* [http://www.medsafe.govt.nz/profs/datasheet/s/Sandomigrantab.pdf Sandomigran drug data sheet] |
||
| Line 89: | Line 193: | ||
| list1 = |
| list1 = |
||
{{Adrenergic receptor modulators}} |
{{Adrenergic receptor modulators}} |
||
{{Dopamine receptor modulators}} |
|||
{{Histamine receptor modulators}} |
{{Histamine receptor modulators}} |
||
{{Muscarinic acetylcholine receptor modulators}} |
{{Muscarinic acetylcholine receptor modulators}} |
||
| Line 97: | Line 202: | ||
[[Category:5-HT2 antagonists]] |
[[Category:5-HT2 antagonists]] |
||
[[Category:Alpha-1 blockers]] |
[[Category:Alpha-1 blockers]] |
||
[[Category:Antimigraine drugs]] |
|||
[[Category:Benzocycloheptathiophenes]] |
[[Category:Benzocycloheptathiophenes]] |
||
[[Category:Dopamine receptor modulators]] |
|||
[[Category:H1 receptor antagonists]] |
[[Category:H1 receptor antagonists]] |
||
[[Category:Muscarinic antagonists]] |
[[Category:Muscarinic antagonists]] |
||
Latest revision as of 21:07, 24 November 2024
 | |
| Clinical data | |
|---|---|
| Trade names | Sandomigran, Mosegor, Litec, others |
| Other names | Pizotyline; BC-105 |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 78% |
| Protein binding | 91% |
| Metabolism | Glucuronidation (main route). N-glucuronide accounts for >50% of plasma and 60–70% of urinary excreted drug |
| Elimination half-life | 23 hours |
| Excretion | 18% feces, 55% urine (both as metabolites) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.036.014 |
| Chemical and physical data | |
| Formula | C19H21NS |
| Molar mass | 295.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pizotifen, also known as pizotyline and sold under the brand names Sandomigran and Mosegor among others, is an antimigraine agent of the tricyclic group which is used primarily as a preventative to reduce the frequency of recurrent migraine headaches.[1]
Medical uses
[edit]Migraine headaches
[edit]The main medical use for pizotifen is for the prevention of migraine and cluster headache. Pizotifen is one of a range of medications used for this purpose, other options include propranolol, topiramate, valproic acid, cyproheptadine and amitriptyline. While pizotifen is effective in adults,[2] evidence of efficacy in children is limited,[3] and its use is limited by side effects, principally drowsiness and weight gain, and it is usually not the first choice medicine for preventing migraines, instead being used as an alternative when other drugs have failed to be effective.[4] It is not effective in relieving migraine attacks once in progress.
Other uses
[edit]Pizotifen has also been reported as highly effective in a severe case of erythromelalgia, a rare neurovascular disease that is sometimes refractory to the other drugs named above.[5]
Other applications for which pizotifen may be used include as an antidepressant, or for the treatment of anxiety or social phobia.[6][7] Animal studies also suggest that pizotyline could be used in the treatment of serotonin syndrome or MDMA overdose[8] in a similar manner to the closely related antihistamine/antiserotonin medication cyproheptadine.
Pizotifen might be useful as a hallucinogen antidote or "trip killer" in blocking the effects of serotonergic psychedelics like psilocybin.[9] It might also be useful in the treatment of MDMA overdose.[10]
Contraindications
[edit]Caution is required in patients having closed angle glaucoma and in patients with a predisposition to urinary retention as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have chronic kidney disease. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of epilepsy. Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen.[11]
Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components, also Pizotifen is contraindicated in gastric outlet obstruction, pregnancy, angle-closure glaucoma and difficulty urinating.[12]
Adverse effects
[edit]Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain.[13] Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.
Pharmacology
[edit]Pharmacodynamics
[edit]| Target | Affinity (Ki, nM) | Species |
|---|---|---|
| 5-HT1A | 200–270 | Human |
| 5-HT1B | 1415 | Human |
| 5-HT1D | 770 | Human |
| 5-HT1E | 820 | Human |
| 5-HT2A | 2.0 | Human |
| 5-HT2B | 2.0–2.3 | Human |
| 5-HT2C | 8.4 | Human |
| 5-HT3 | 95 | Human |
| 5-HT4 | ND | Human |
| 5-HT5A | 110 | Human |
| 5-HT6 | 74 | Human |
| 5-HT7 | 17–25 | Human |
| D1 | 3.5 | Human |
| D2 | 2.4–87 | Human |
| D3 | ND | ND |
| D4 | 64 | Human |
| D5 | 50 | Human |
| α1A | 65 | Human |
| α1B | >10000 | Human |
| α2A | 660 | Human |
| α2B | 225 | Human |
| α2C | 390 | Human |
| β1 | >10000 | Human |
| β2 | >10000 | Human |
| H1 | 1.9 | Human |
| H2 | 1.4 | Human |
| M1 | 67 | Human |
| M2 | 34 | Human |
| M3 | 29 | Human |
| M4 | 130 | Human |
| M5 | 6.8 | Human |
| I1 receptor | 121 | Human |
| σ1 receptor | >10000 | Guinea pig |
| σ2 receptor | 6450 | Rat |
| SERT | >10000 | Human |
| NET | 710 | Human |
| DAT | >10000 | Human |
| Note: The smaller the value, the more avidly the compound binds to or activates the site. Refs: [14][15][16][10][17] | ||
Pizotifen is a serotonin antagonist acting mainly at the 5-HT2A and 5-HT2C receptors. It also has some activity as an antihistamine as well as some anticholinergic activity.[18] The drug binds non-selectivey to many targets, including serotonin, dopamine, adrenergic, histamine, and muscarinic acetylcholine receptors.[10]
Pizotifen is able to dose-dependently and fully antagonize the discriminative stimulus effects of the serotonin–norepinephrine–dopamine releasing agent and serotonin 5-HT2 receptor agonist MDMA in rodent drug discrimination tests.[10] Conversely, the related drug cyproheptadine was only partially effective and clozapine was ineffective.[10] All three of these agents, pizotifen, cyproheptadine, and clozapine act as non-selective monoamine receptor antagonists.[10] Pizotifen also fully blocks the effects of serotonergic psychedelics, including LSD, mescaline, 5-MeO-DMT, and DOM, in drug discrimination tests.[10]
Chemistry
[edit]Pizotifen is a tricyclic compound and is specifically a benzocycloheptene.[19][20]
Close analogues of pizotifen include ketotifen and cyproheptadine, among others.
History
[edit]Pizotifen was first described in the literature by 1964.[19]
Society and culture
[edit]Names
[edit]Pizotifen is the generic name of the drug and its INN and BAN, while pizotyline is its USAN.[19][20][21] Brand names of pizotifen include Sandomigran, Mosegor, and Litec, among others.[19][20][21][22]
Availability
[edit]Pizotifen is available widely throughout the world, including in Europe.[20][22]
References
[edit]- ^ Stark RJ, Valenti L, Miller GC (August 2007). "Management of migraine in Australian general practice". The Medical Journal of Australia. 187 (3): 142–146. doi:10.5694/j.1326-5377.2007.tb01170.x. PMID 17680738. S2CID 10357983.
- ^ Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. (2015-07-14). "A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache". PLOS ONE. 10 (7): e0130733. Bibcode:2015PLoSO..1030733J. doi:10.1371/journal.pone.0130733. PMC 4501738. PMID 26172390.
- ^ Barnes N, Millman G (July 2004). "Do pizotifen or propranolol reduce the frequency of migraine headache?". Archives of Disease in Childhood. 89 (7): 684–685. doi:10.1136/adc.2004.054668. PMC 1719986. PMID 15210509.
- ^ Pierangeli G, Cevoli S, Sancisi E, Grimaldi D, Zanigni S, Montagna P, Cortelli P (May 2006). "Which therapy for which patient?". Neurological Sciences. 27 (Suppl 2): S153–S158. doi:10.1007/s10072-006-0592-0. PMID 16688621. S2CID 24217802.
- ^ Cohen JS (November 2000). "Erythromelalgia: new theories and new therapies". Journal of the American Academy of Dermatology. 43 (5 Pt 1): 841–847. doi:10.1067/mjd.2000.109301. PMID 11050591. S2CID 40807034.
- ^ Standal JE (October 1977). "Pizotifen as an antidepressant". Acta Psychiatrica Scandinavica. 56 (4): 276–279. doi:10.1111/j.1600-0447.1977.tb00228.x. PMID 335788. S2CID 6445059.
- ^ Banki CM (March 1978). "Clinical observations with pizotifene (Sandomigran) in the treatment of nonmigrainous depressed women". Archiv für Psychiatrie und Nervenkrankheiten. 225 (1): 67–72. doi:10.1007/bf00367352. PMID 348154. S2CID 13510725.
- ^ Young R, Khorana N, Bondareva T, Glennon RA (October 2005). "Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA)". Pharmacology, Biochemistry, and Behavior. 82 (2): 404–410. doi:10.1016/j.pbb.2005.09.010. PMID 16253319. S2CID 20885754.
- ^ Halman A, Kong G, Sarris J, Perkins D (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". J Psychopharmacol. 38 (1): 3–18. doi:10.1177/02698811231211219. PMC 10851641. PMID 37982394.
- ^ a b c d e f g Young R, Khorana N, Bondareva T, Glennon RA (October 2005). "Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA)". Pharmacol Biochem Behav. 82 (2): 404–410. doi:10.1016/j.pbb.2005.09.010. PMID 16253319.
- ^ "SANDOMIGRAN® pizotifen 500 micrograms coated tablets" (PDF). AFT Pharmaceuticals Ltd. Medsafe: New Zealand Medicines and Medical Devices Safety. 21 June 2019.
- ^ "Pizotifen". Universal reference book of medicines – via Likarstwo.ru.
- ^ Crowder D, Maclay WP. Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study. Current Medical Research and Opinion. 1984;9(4):280-5.
- ^ "PDSP Database". UNC (in Zulu). Retrieved 24 November 2024.
- ^ "PDSP Database". UNC (in Zulu). Retrieved 24 November 2024.
- ^ Liu T. "BindingDB BDBM82088 CAS_15574-96-6::NSC_27400::PIZOTIFEN". BindingDB. Retrieved 24 November 2024.
- ^ Moritomo A, Yamada H, Watanabe T, Itahana H, Akuzawa S, Okada M, Ohta M (December 2013). "Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists". Bioorg Med Chem. 21 (24): 7841–7852. doi:10.1016/j.bmc.2013.10.010. PMID 24189186.
- ^ Dixon AK, Hill RC, Roemer D, Scholtysik G (1977). "Pharmacological properties of 4(1-methyl-4-piperidylidine)-9,10-dihydro-4H-benzo-[4,5]cyclohepta[1,2]-thiophene hydrogen maleate (pizotifen)". Arzneimittel-Forschung. 27 (10): 1968–1979. PMID 411500.
- ^ a b c d Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1002. ISBN 978-1-4757-2085-3. Retrieved 24 November 2024.
- ^ a b c d Schweizerischer Apotheker-Verein (2004). Index Nominum: International Drug Directory. Index Nominum: International Drug Directory. Medpharm Scientific Publishers. p. 992. ISBN 978-3-88763-101-7. Retrieved 24 November 2024.
- ^ a b Morton I, Hall J (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 225. ISBN 978-94-011-4439-1. Retrieved 24 November 2024.
- ^ a b "Pizotifen (International database)". Drugs.com. 3 November 2024. Retrieved 24 November 2024.